• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用外泌体包裹川芎嗪靶向逆转卵巢癌细胞的多药耐药性。

Targeted reversal of multidrug resistance in ovarian cancer cells using exosome‑encapsulated tetramethylpyrazine.

机构信息

Department of Pharmacy, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China.

出版信息

Mol Med Rep. 2024 Feb;29(2). doi: 10.3892/mmr.2023.13148. Epub 2023 Dec 15.

DOI:10.3892/mmr.2023.13148
PMID:38099342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10784732/
Abstract

The objective of the present study was to develop exosomes (EXOs) encapsulating tetramethylpyrazine (TMP) for the reversal of drug resistance in ovarian cancer therapy. Human A2780 cells were incubated with TMP for 48 h. Purified TMP‑primed EXOs (EXOs‑TMP) were isolated through ultracentrifugation. The developed EXOs‑TMP were characterized using techniques such as transmission electron microscopy, nanoparticle tracking analysis, Fluorescence microscopy and western blotting. Subsequently, MTT, western blotting and flow cytometry assays were performed to evaluate the biological effects in drug‑resistant A2780T cells. The results demonstrated that the incorporation of TMP into EXOs exhibited an anti‑ovarian cancer effect and markedly enhanced the antitumor efficacy of paclitaxel (PTX). Furthermore, it was identified that the ability of EXO‑TMP to reverse cell resistance was associated with the downregulation of multidrug resistance protein 1, multidrug resistant‑associated protein 1 and glutathione S‑transferase Pi protein expression. Flow cytometry analysis revealed that EXO‑TMP induced apoptosis in drug‑resistant cells and enhanced the apoptotic effect when combined with PTX. EXOs are naturally sourced, exhibit excellent biocompatibility and enable precise drug delivery to target sites, thereby reducing toxic side effects. Overall, EXO‑TMP exhibited direct targeting capabilities towards A2780T cells and effectively reduced their drug resistance. EXOs‑TMP provide a novel and effective drug delivery pathway for reversing drug resistance in ovarian cancer.

摘要

本研究旨在开发载有川芎嗪(TMP)的外泌体(EXOs),以逆转卵巢癌治疗中的耐药性。将人 A2780 细胞与 TMP 孵育 48 h。通过超速离心分离纯化 TMP 预载的 EXOs(EXOs-TMP)。采用透射电子显微镜、纳米颗粒跟踪分析、荧光显微镜和 Western blot 等技术对所开发的 EXOs-TMP 进行表征。随后,通过 MTT、Western blot 和流式细胞术检测评估耐药 A2780T 细胞中的生物学效应。结果表明,TMP 被包裹于 EXOs 中表现出抗卵巢癌作用,并显著增强紫杉醇(PTX)的抗肿瘤疗效。此外,研究发现 EXO-TMP 逆转细胞耐药的能力与多药耐药蛋白 1、多药耐药相关蛋白 1 和谷胱甘肽 S-转移酶 Pi 蛋白表达下调有关。流式细胞术分析显示,EXO-TMP 诱导耐药细胞凋亡,并与 PTX 联合增强凋亡效应。EXOs 具有天然来源、优异的生物相容性,并能精确地将药物递送至靶位,从而减少毒副作用。总体而言,EXO-TMP 对 A2780T 细胞具有直接靶向作用,并有效降低其耐药性。EXO-TMP 为逆转卵巢癌耐药提供了一种新的有效药物递送途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/c0a908ce395c/mmr-29-02-13148-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/814cfd43fc75/mmr-29-02-13148-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/a013eaa213e7/mmr-29-02-13148-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/972d28d75afb/mmr-29-02-13148-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/afebd71dc66e/mmr-29-02-13148-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/6dca5179f203/mmr-29-02-13148-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/c0a908ce395c/mmr-29-02-13148-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/814cfd43fc75/mmr-29-02-13148-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/a013eaa213e7/mmr-29-02-13148-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/972d28d75afb/mmr-29-02-13148-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/afebd71dc66e/mmr-29-02-13148-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/6dca5179f203/mmr-29-02-13148-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88b0/10784732/c0a908ce395c/mmr-29-02-13148-g05.jpg

相似文献

1
Targeted reversal of multidrug resistance in ovarian cancer cells using exosome‑encapsulated tetramethylpyrazine.利用外泌体包裹川芎嗪靶向逆转卵巢癌细胞的多药耐药性。
Mol Med Rep. 2024 Feb;29(2). doi: 10.3892/mmr.2023.13148. Epub 2023 Dec 15.
2
Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.通关藤注射液通过上调TAB1表达在体内外逆转卵巢癌对紫杉醇的耐药性。
J Ethnopharmacol. 2023 Jan 10;300:115728. doi: 10.1016/j.jep.2022.115728. Epub 2022 Sep 17.
3
Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect.自然杀伤细胞衍生的外泌体包裹的紫杉醇可以增强其抗肿瘤效果。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5703-5713. doi: 10.26355/eurrev_202005_21362.
4
Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation.M1 极化巨噬细胞来源的外泌体通过激活巨噬细胞介导的炎症增强紫杉醇的抗肿瘤活性。
Theranostics. 2019 Feb 28;9(6):1714-1727. doi: 10.7150/thno.30716. eCollection 2019.
5
The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer SKOV3 Cells.雷公藤红素负载的外泌体对人卵巢癌 SKOV3 细胞增殖和凋亡的影响。
Biomed Res Int. 2019 May 21;2019:2595801. doi: 10.1155/2019/2595801. eCollection 2019.
6
Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.由二硫键连接的紫杉醇-川芎嗪共轭物自组装而成的氧化还原敏感型无载体纳米颗粒用于联合癌症化疗。
Theranostics. 2021 Feb 20;11(9):4171-4186. doi: 10.7150/thno.42260. eCollection 2021.
7
Umbilical Cord Blood-Derived M1 Macrophage Exosomes Loaded with Cisplatin Target Ovarian Cancer and Reverse Cisplatin Resistance.载顺铂的脐带血源性 M1 巨噬细胞胞外体靶向卵巢癌并逆转顺铂耐药性。
Mol Pharm. 2023 Nov 6;20(11):5440-5453. doi: 10.1021/acs.molpharmaceut.3c00132. Epub 2023 Oct 11.
8
Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.载姜黄素和紫杉醇的“核壳”靶向两亲性共聚物逆转卵巢癌细胞耐药性的治疗作用
Int J Nanomedicine. 2019 Dec 2;14:9453-9467. doi: 10.2147/IJN.S224579. eCollection 2019.
9
Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.格尔德霉素,一种热休克蛋白90(Hsp90)抑制剂,通过持续激活p38/H2AX轴增加紫杉醇对卵巢癌细胞的毒性作用。
Tumour Biol. 2016 Nov;37(11):14745-14755. doi: 10.1007/s13277-016-5297-2. Epub 2016 Sep 15.
10
Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.紫杉醇诱导卵巢癌细胞系多药耐药的机制分析
Asian Pac J Cancer Prev. 2013;14(9):4983-8. doi: 10.7314/apjcp.2013.14.9.4983.

引用本文的文献

1
Exosomes in ovarian cancer: Impact on drug resistance and advances in SERS detection techniques.卵巢癌中的外泌体:对耐药性的影响及表面增强拉曼散射检测技术的进展
J Pharm Anal. 2025 Jul;15(7):101170. doi: 10.1016/j.jpha.2024.101170. Epub 2024 Dec 18.
2
Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer.利用细胞外囊泡实现卵巢癌的靶向药物递送
Pharmaceutics. 2025 Apr 17;17(4):528. doi: 10.3390/pharmaceutics17040528.
3
Uptake of Biomimetic Nanovesicles by Granuloma for Photodynamic Therapy of Tuberculosis.

本文引用的文献

1
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy.外泌体 LOC85009 通过调节 ATG5 诱导的自噬抑制肺腺癌对多西他赛的耐药性。
Drug Resist Updat. 2023 Mar;67:100915. doi: 10.1016/j.drup.2022.100915. Epub 2022 Dec 26.
2
Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer.抑制未折叠蛋白反应的 IRE1α 轴增强 TP53 突变型卵巢癌中 AZD1775 的抗肿瘤作用。
Adv Sci (Weinh). 2022 Jul;9(21):e2105469. doi: 10.1002/advs.202105469. Epub 2022 May 26.
3
Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature.
肉芽肿对用于结核病光动力治疗的仿生纳米囊泡的摄取
ACS Omega. 2025 Feb 11;10(7):6679-6688. doi: 10.1021/acsomega.4c08127. eCollection 2025 Feb 25.
4
Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells.微小RNA-152-3p介导的紫杉醇耐药卵巢癌细胞自噬及敏感性调控机制
Onco Targets Ther. 2025 Feb 4;18:179-197. doi: 10.2147/OTT.S485100. eCollection 2025.
基于纳米载体的药物传递系统用于脑靶向的潜力:文献综述。
Int J Nanomedicine. 2021 Nov 11;16:7517-7533. doi: 10.2147/IJN.S333657. eCollection 2021.
4
GSTP1 as a novel target in radiation induced lung injury.谷胱甘肽 S-转移酶 P1 作为放射性肺损伤的一个新靶点。
J Transl Med. 2021 Jul 8;19(1):297. doi: 10.1186/s12967-021-02978-0.
5
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.克服 PARPi 耐药性:卵巢癌的临床前和临床证据。
Drug Resist Updat. 2021 Mar;55:100744. doi: 10.1016/j.drup.2021.100744. Epub 2021 Jan 16.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance.多药耐药蛋白(MRPs):结构、功能与克服肿瘤多药耐药性。
Drug Resist Updat. 2021 Jan;54:100743. doi: 10.1016/j.drup.2021.100743. Epub 2021 Jan 13.
8
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?ABCB1、ABCG2、ABCC1、ABCC2和ABCC3药物转运体多态性及其对药物生物利用度的影响:我们目前的认识是什么?
Expert Opin Drug Metab Toxicol. 2021 Apr;17(4):369-396. doi: 10.1080/17425255.2021.1876661. Epub 2021 Feb 2.
9
Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211.川芎嗪通过调节 miR-211 抑制卵巢癌细胞的增殖和迁移。
Biosci Rep. 2021 Jan 29;41(1). doi: 10.1042/BSR20200199.
10
Nanoparticle delivery systems to combat drug resistance in ovarian cancer.纳米颗粒递药系统克服卵巢癌耐药性。
Nanomedicine. 2021 Jan;31:102309. doi: 10.1016/j.nano.2020.102309. Epub 2020 Sep 28.